GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunny Pharmtech 6676.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

8.03

+15.04%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sunny Pharmtech

Its shares trade on Taipei Exchange under the ticker 6676.TWO. It has been listed since 19 January 2022. In the fiscal year to 31 December 2024, it reported revenue of TWD 418.0m and a net loss of TWD 156.0m. At that date it held total assets of TWD 1.59bn and shareholders' equity of TWD 1.05bn.

Sunny Pharmtech, Inc. operates as a pharmaceutical company that engages in developing, manufacturing and marketing generic and 505(b)2 drug products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2022-01-19. The main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia and campto (CPT) gynecological injections. The firm's products are mainly sold to the United States.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Jan 2022
Employees
123

Leadership

Pay as last reported

  • Mr. Yon-Lian WuChairman of the Board, Chief Executive Officer, since 2022
  • Mr. Kun-Hung TsaiChief Financial Officer, Head of Finance & Accounting
  • Ms. Yongyi ChenDeputy General Manager-Operation Center
  • Mr. Rongyi HuangDirector
  • Mr. Qirui LiDirector
  • Mr. Tsung-Jung LiDirector
  • Mr. Tung-He LinDirector
  • Mr. Lien-Tzu LiIndependent Director
  • Mr. Zhi-Hong LiuIndependent Director
  • Mr. Yi-Ming SunIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taoyuan, Taiwan with 123 employees
  • Operates in the Pharmaceuticals sector within Health Care
  • IPO occurred on 2022-01-19

Weaknesses

  • Products primarily sold to the United States market
  • Relies on generic and 505(b)2 drug products development
  • Limited product diversity as per listed main products

Opportunities

  • Potential growth in generic drug market
  • Expansion into new markets beyond United States
  • Increased demand for pharmaceutical products

Threats

  • Dependence on specific product lines like LDC and CPT
  • Competition in the pharmaceutical industry
  • Market volatility affecting drug sales

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.